

# Haplotype-Based Methods for Detecting Uncommon Causal Variants With Common SNPs

Wan-Yu Lin,<sup>1</sup> Nengjun Yi,<sup>2</sup> Degui Zhi,<sup>2</sup> Kui Zhang,<sup>2</sup> Guimin Gao,<sup>3</sup> Hemant K. Tiwari,<sup>2</sup> and Nianjun Liu<sup>2\*</sup>

<sup>1</sup>Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan

<sup>2</sup>Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama

<sup>3</sup>Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia

Detecting uncommon causal variants (minor allele frequency [MAF] < 5%) is difficult with commercial single-nucleotide polymorphism (SNP) arrays that are designed to capture common variants (MAF > 5%). Haplotypes can provide insights into underlying linkage disequilibrium (LD) structure and can tag uncommon variants that are not well tagged by common variants. In this work, we propose a *wei-SIMc-matching* test that inversely weights haplotype similarities with the estimated standard deviation of haplotype counts to boost the power of similarity-based approaches for detecting uncommon causal variants. We then compare the power of the *wei-SIMc-matching* test with that of several popular haplotype-based tests, including four other similarity-based tests, a global score test for haplotypes (*global*), a test based on the maximum score statistic over all haplotypes (*max*), and two newly proposed haplotype-based tests for rare variant detection. With systematic simulations under a wide range of LD patterns, the results show that *wei-SIMc-matching* and *global* are the two most powerful tests. Among these two tests, *wei-SIMc-matching* has reliable asymptotic *P*-values, whereas *global* needs permutations to obtain reliable *P*-values when the frequencies of some haplotype categories are low or when the trait is skewed. Therefore, we recommend *wei-SIMc-matching* for detecting uncommon causal variants with surrounding common SNPs, in light of its power and computational feasibility. *Genet. Epidemiol.* 36:572–582, 2012. © 2012 Wiley Periodicals, Inc.

**Key words:** haplotype; similarity; linkage disequilibrium; rare variants

Supporting Information is available in the online issue at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).

\*Correspondence to: Nianjun Liu, Department of Biostatistics, University of Alabama at Birmingham, Ryals Public Health Building 327, 1665 University Boulevard, Birmingham, AL 35294. E-mail: [nliu@uab.edu](mailto:nliu@uab.edu)

Received 29 January 2012; Revised 19 April 2012; Accepted 9 May 2012

Published online 15 June 2012 in Wiley Online Library ([wileyonlinelibrary.com/journal/gepi](http://wileyonlinelibrary.com/journal/gepi)).

DOI: 10.1002/gepi.21650

## INTRODUCTION

In the past few years, genome-wide association studies (GWAS) have identified hundreds of common genetic variants (minor allele frequency [MAF] > 5%) for complex human diseases. However, these common variants can only explain a small proportion of heritability [Manolio et al., 2009]. Uncommon variants (MAF < 5%) are likely to play an important role in the missing heritability that cannot be explained by common variants. In this work, we call the variants with MAF < 5% “uncommon variants,” including the so-called “rare variants” (MAF < 1%) and “low-frequency variants” (MAF 1–5%) [Zeggini, 2011]. Searching for uncommon variants that are responsible for complex diseases is now attracting more attention [Zeggini, 2011]. However, this topic remains challenging. When sequencing data are available, pooling signals of multiple uncommon variants and testing the association of this pooled set with the disease [Han and Pan, 2010; Li and Leal, 2008; Madsen and Browning, 2009; Morris and Zeggini, 2010; Price et al., 2010] is an attractive strategy [Lin et al., 2011]. However, due to the high cost of sequencing [Sboner et al., 2011], GWAS data are still the most commonly available data in the current stage [Li et al., 2010; WTCCC, 2007]. For GWAS using commercial single-nucleotide polymorphism (SNP) arrays, the

pooling methods are underpowered in detecting uncommon causal variants as they pool signals of common SNPs that cannot well represent the information of uncommon variants (this argument should be apparent and the pooling methods were mainly proposed for sequencing data with rare variants, but we still include them into the following comparisons). Similarly, conventional single-marker analysis is also underpowered because markers in commercial SNP arrays cannot be good surrogates for causal variants that are too rare [Gusev et al., 2011].

Haplotypes can provide insights into underlying linkage disequilibrium (LD) structure and can tag uncommon causal variants that are not well tagged by common SNPs [Gusev et al., 2011; Li et al., 2010]. For some complex diseases such as hypertension, rare haplotypes have been shown to influence the disease susceptibility [Kitsios and Zintzaras, 2010; Liu et al., 2005; Zhu et al., 2005]. A recent study has shown that identical-by-descent haplotype mapping is powerful for tagging rare variants [Gusev et al., 2011]. In addition, similarity-based approach has been used in uncommon and common variant detection [Tzeng et al., 2011]. These studies suggest that similarity-based approaches might be also useful, to some extent, in detecting uncommon causal variants using nearby common SNPs.

In this work, we propose a “*wei-SIMc-matching*” test to capture the signals of uncommon causal variants using haplotype information. We inversely weight haplotype similarities with the estimated standard deviation of haplotype counts to boost the power of similarity-based approaches for detecting uncommon causal variants. We then compare the performance of *wei-SIMc-matching* with that of several popular haplotype methods. We show that although commercial SNP arrays are not designed to capture uncommon causal variants, some haplotype methods including the proposed *wei-SIMc-matching* test have a better ability to complement this.

## METHODS

### SIMILARITY-BASED TESTS

**Statistical model.** Let  $y_i$  be the phenotype of the  $i$ th subject ( $i = 1, \dots, N$ ), and let  $\Gamma(h_i)$  be a  $k \times 1$  vector coding the frequencies of all “haplotype categories” for the  $i$ th subject, where  $k$  is the number of “haplotype categories” (i.e., unique haplotypes in the sample, two haplotypes are classified into a same *category* if all observed alleles on the two haplotypes are the same). For example, if there are three categories of haplotypes  $\{h^1, h^2, h^3\}$  and both of the haplotypes of the  $i$ th subject are  $h^1$ , then  $\Gamma(h_i)^T = [1 \ 0 \ 0]$ , where  $\Gamma(h_i)^T$  is the transpose of  $\Gamma(h_i)$ . If one haplotype is  $h^2$  and the other is  $h^3$ , then  $\Gamma(h_i)^T = [0 \ 0.5 \ 0.5]$ . When the haplotype phase is uncertain, statistical methods such as the expectation-maximization (EM) algorithm [Dempster et al., 1977] can be used to infer the haplotype frequency vector, under the assumption of Hardy-Weinberg equilibrium (HWE) [Excoffier and Slatkin, 1995; Hawley and Kidd, 1995; Long et al., 1995].

We consider a generalized linear model:

$$g(E(Y)) = C\alpha + x\beta, \quad (1)$$

where  $g(\cdot)$  is a link function,  $Y$  is an  $N$ -length vector of phenotypes,  $C$  is an  $N \times (m + 1)$  matrix with the  $i$ th row of  $c_i^T = [1 \ c_{i,1} \ c_{i,2} \ \dots \ c_{i,m}]$  coding 1 (for the intercept term), and  $m$  covariates (e.g., age, gender, ethnicity, etc.) of the  $i$ th subject,  $\alpha$  is the  $(m + 1)$ -element vector of covariate effects including the intercept term,  $x$  is an  $N$ -length vector with the  $i$ th element of  $x_i = \gamma^T \cdot S \cdot \Gamma(h_i)$  coding the genetic information (regarding the region under investigation) of the  $i$ th subject, and  $\beta$  is the regression coefficient of the genetic information coded by  $x$ . The scalar  $x_i = \gamma^T \cdot S \cdot \Gamma(h_i)$  is a quantity comparing the  $i$ th subject’s haplotypes against haplotypes of all the other subjects, in which  $\Gamma(h_i)$  is the haplotype frequency vector of the  $i$ th subject,  $\gamma$  is a specified vector aggregating the haplotype information of all the  $N$  subjects, and  $S$  is a  $k \times k$  matrix whose  $(v, v)$  element is the similarity between the  $v$ th and  $v$ th categories of haplotypes. The canonical link is the *logit* function ( $g(\mu) = \log \frac{\mu}{1-\mu}$ ), the *identity* function ( $g(\mu) = \mu$ ), and the *log* function ( $g(\mu) = \log \mu$ ) given binary traits, normally distributed traits, and traits with Poisson distribution, respectively [Nelder and Wedderburn, 1972].

**Test statistics.** Based on the model in Equation (1) and under the assumption of gene-covariate independence, the

score statistic is

$$U = \gamma^T \cdot S \cdot \sum_{i=1}^N \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i), \quad (2)$$

where  $\hat{\mu}_i = c_i^T (C^T C)^{-1} (C^T Y)$  is the fitted value of the  $i$ th subject according to the covariates;  $a(\phi)$  is the mean square error if the trait distribution is normal, and is 1 if the trait distribution is Bernoulli or Poisson [Nelder and Wedderburn, 1972]. With different specification of  $\gamma$ , the score statistic can result in different tests.

When we specify  $\gamma = \frac{1}{N} \sum_{i=1}^N \Gamma(h_i) \equiv \hat{p}$ , where  $\hat{p}$  is the vector of the average haplotype frequencies of all the  $N$  subjects, the resulting test is called *SIMP* with the test statistic

$$T_{SIMP} = \frac{\left[ \hat{p}^T S \sum_{i=1}^N \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i) \right]^2}{\hat{p}^T S \hat{\Omega} S \hat{p}}, \quad (3)$$

where  $\hat{\Omega}$  is the estimated variance-covariance matrix of  $\sum_{i=1}^N \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i)$  [Lin et al., 2012] and

$$\hat{\Omega} = \sum_{i=1}^N \left[ \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i) \right] \left[ \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i) \right]^T - \frac{1}{N} \left[ \sum_{i=1}^N \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i) \right] \left[ \sum_{i=1}^N \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i) \right]^T.$$

Because  $T_{SIMP}$  is the square of a standard normal variable, it has an asymptotic  $\chi^2$  distribution with one degree of freedom.

When we specify  $\gamma = \sum_{i=1}^N \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i)$ , the resulting test is called *SIMc* with the test statistic

$$T_{SIMc} = \left[ \sum_{i=1}^N \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i) \right]^T S \left[ \sum_{i=1}^N \frac{(y_i - \hat{\mu}_i)}{a(\phi)} \Gamma(h_i) \right]. \quad (4)$$

By the theory of quadratic forms of normal variables [Scheffe, 1959],  $T_{SIMc}$  is asymptotically distributed as  $\sum_{i=1}^{\varpi} \lambda_i \chi_{1,i}^2$ , where  $\chi_{1,i}^2$ ’s are independent  $\chi^2$  variables with one degree of freedom, and  $\lambda_1 \geq \lambda_2 \geq \dots \geq \lambda_{\varpi}$  are the ordered eigen values of the matrix  $\hat{\Omega} S$  ( $\varpi$  is the rank of the matrix  $\hat{\Omega} S$ ). The distribution of  $T_{SIMc}$  can be approximated by the three-moment approximation method [Allen and Satten, 2007, 2009; Imhof, 1961; Tzeng et al., 2009]. The  $P$ -value of the observed *SIMc* test statistic is given by

$$P \left( \chi_b^2 > (T_{SIMc} - c_1) \times \sqrt{\frac{b}{c_2} + b} \right),$$

where  $c_j = \sum_{i=1}^{\varpi} \lambda_i^j$ ,  $b = c_3^2 / c_2^2$ , and  $\chi_b^2$  is the  $\chi^2$  distribution with  $b$  degrees of freedom.

The similarity matrix  $S$  can be constructed based on metrics such as the counting measure or the matching measure [Tzeng et al., 2003]. The counting measure calculates the percentage of alleles in common between any two haplotypes;

the matching measure treats each haplotype as a distinct category and is defined as 1 if two haplotypes match and 0 otherwise. Therefore, the similarity matrix  $\mathbb{S}$  is a matrix with all diagonal elements of 1 and all off-diagonal elements of 0, if the matching measure is employed. Both the two similarity-based tests (*SIMp* and *SIMc*) can be respectively equipped with the counting measure and the matching measure, resulting in four tests (*SIMp-counting*, *SIMp-matching*, *SIMc-counting*, and *SIMc-matching*).

**Weighting similarities.** Previous studies show that uncommon causal variants usually have larger effect sizes compared to common causal variants [Bodmer and Bonilla, 2008]. Moreover, uncommon variants are more likely to be tagged by uncommon haplotypes than by common haplotypes. Therefore, up-weighting uncommon haplotypes may facilitate the discoveries of uncommon variants. Li et al. [2010] defined  $S_h = [N_{ct} \cdot f_{ct,h} \cdot (1 - f_{ct,h})]^{-1/2}$  ( $h = 1, \dots, k$ , in which  $k$  is the number of haplotype categories), where  $N_{ct}$  is the number of controls;  $f_{ct,h}$  is the adjusted frequency of haplotype  $h$  among controls and is quantified as  $f_{ct,h} = \frac{C_{ct,h+1}}{(2N_{ct}+2)}$ , in which  $C_{ct,h}$  is the number of haplotype  $h$  among controls. We let the  $k \times k$  similarity matrix  $\mathbb{S}$  be a diagonal matrix with the  $h$ th diagonal element of  $S_h = [N_{ct} \cdot f_{ct,h} \cdot (1 - f_{ct,h})]^{-1/2}$ , where  $h = 1, 2, \dots, k$ . When continuous traits are analyzed, we let  $S_h = [N \cdot f_h \cdot (1 - f_h)]^{-1/2}$ , where  $N$  is the total number of subjects and  $f_h = \frac{C_h+1}{(2N+2)}$ , in which  $C_h$  is the number of haplotype  $h$  among all the  $N$  subjects.

We plug this similarity matrix  $\mathbb{S}$  into Equation (4), and the resulting test is referred to as the *wei-SIMc-matching* test. It is based on the *SIMc* test with the matching measure inversely weighted by the estimated standard deviation of haplotype counts. The weighting scheme given to haplotypes is inspired from Madsen and Browning's weights for SNPs [Madsen and Browning, 2009]. Using this weight in  $\mathbb{S}$  implies that we up-weight the similarities contributed by uncommon haplotypes but down-weight the similarities contributed by common haplotypes. Presumably, *wei-SIMc-matching* can boost the power of similarity-based approaches for detecting uncommon causal variants. We will evaluate its performance with simulations.

## STANDARD HAPLOTYPE REGRESSION TESTS

A global score test for haplotypes (*global*) and a test based on the maximum score statistic over all haplotypes (*max*) have been widely used for detecting common variants [Schaid et al., 2002]. The *global* test is regarded as a standard haplotype regression and is usually compared with similarity-based tests [Lin and Schaid, 2009; Lin et al., 2012; Tzeng et al., 2009, 2011]. The *global* and *max* tests are based on a generalized linear model:

$$g(E(\mathbf{Y})) = \mathbf{C}\boldsymbol{\eta} + \mathfrak{Z}\boldsymbol{\psi}, \quad (5)$$

where  $g(\cdot)$  is a link function,  $\mathfrak{Z}$  is an  $N \times k$  matrix with the  $i$ th row of  $\boldsymbol{\Gamma}(h_i)^T$  (the transpose of the haplotype-frequency vector of the  $i$ th subject),  $\boldsymbol{\eta}$  is the  $(m+1)$ -element vector of covariate effects including the intercept term, and  $\boldsymbol{\psi}$  is the  $k$ -element vector of the regression coefficients for the  $k$  categories of haplotypes in the region. Let  $\mathbf{U}_\psi$  be the score vector of  $\boldsymbol{\psi}$ , and  $\mathbf{V}_\psi$  be the variance-covariance matrix of

$\mathbf{U}_\psi$ . The *global* score statistic is  $T_{global} = \mathbf{U}_\psi^T \mathbf{V}_\psi^{-1} \mathbf{U}_\psi$ , which has an asymptotic  $\chi^2$  distribution with degrees of freedom equal to the rank of  $\mathbf{V}_\psi$  [Schaid et al., 2002].

The maximum score statistic over all haplotypes is  $T_{max} = \max_k (U_{\psi,k}^2 / V_{\psi,k,k})$ , where  $U_{\psi,k}$  is the  $k$ th element of  $\mathbf{U}_\psi$  and  $V_{\psi,k,k}$  is the  $(k, k)$  element of  $\mathbf{V}_\psi$ . There is no analytic form for the distribution function of the *max* test statistic, so permutation  $P$ -values are used in practice [Schaid et al., 2002].

## HAPLOTYPE-BASED TESTS TO DETECT RARE VARIANTS

Recently, two haplotype-based tests were proposed for rare variant detection. Both the two tests split the data into a training set and a testing set. Zhu et al.'s haplotype grouping test (referred to as "*HG*") classifies haplotypes as risk or nonrisk with the training set (the co-classification stage), and then tests for associations by performing a Fisher's exact test with the testing set (the association stage) [Zhu et al., 2010]. This method has been applied to the Wellcome Trust Case Control Consortium (WTCCC) data [Feng and Zhu, 2010]. Li et al.'s weighted haplotype test on genotyped SNPs (referred to as "*WHG*") is based on a similar procedure. The *WHG* further boosts power to detect rare variants by weighting haplotypes according to their frequencies [Li et al., 2010]. For both *HG* and *WHG*, we followed Li et al. [2010] to randomly select 30% of the sample as the training set and let the remaining 70% be the testing set.

## SIMULATION STUDY

Following Li et al.'s simulation [2010], we first generated 200 data sets each containing 10,000 chromosomes of 1 Mb regions with the *Cosi* program [Schaffner et al., 2005]. The chromosomes were generated in consistency with the HapMap CEU (CEPH people from Utah, USA, <http://hapmap.ncbi.nlm.nih.gov/>) samples. For each data set, we randomly picked an  $\sim 50$  kb region as the causal region, within the 1 Mb region. Within each causal region, we randomly selected  $d$  variants with population MAF between 0.1% and 5% ( $d = 5, 10, 20, 30, \text{ or } 40$ ), and we treated these variants as causal variants that might increase or decrease the disease risk (or the value of a continuous trait). Among the  $d$  causal variants, we let  $r\%$  of them increase the disease risk while the remaining  $(100 - r)\%$  decrease the disease risk (or the value of a continuous trait). The value of  $r$  was specified at 5, 20, 50, 80, and 100, respectively. In each data set, we randomly chose 120 from the 10,000 chromosomes to mimic the Phase II HapMap CEU data, and these 120 chromosomes were randomly paired to form 60 subjects. Based on the LD patterns of the 60 subjects, tag SNPs were selected according to the conventional criterion of  $r^2 = 0.8$  and  $\text{MAF} > 5\%$  (many association studies for complex human diseases tend to use SNPs with  $\text{MAF} > 5\%$  due to a power consideration [Barrett and Cardon, 2006; Keating et al., 2008]), with the *H-clust* method [Rinaldo et al., 2005; Roeder et al., 2005]. These tag SNPs were served as markers used in our simulations.

## BINARY TRAITS

When evaluating the type-I error rates, the population attributable risk (PAR) was set at 0%. When evaluating the power, the PAR of each causal variant was set at 0.2%, 0.4%, 0.6%, 0.8%, and 1.0%, respectively. We follow previous studies [Li et al., 2010; Madsen and Browning, 2009] to assign larger genetic effects to rarer variants, because rare variants with a chance to be detected usually have larger effect sizes compared to common variants [Bodmer and Bonilla, 2008]. The genotype relative risk (GRR) of a causal variant  $j$  with PAR of  $PAR_j$  and MAF of  $MAF_j$  is

$$GRR_j = \left( \frac{PAR_j}{(1 - PAR_j) \cdot MAF_j} + 1 \right)^{(-1)^{I(\xi_j=1)}}, \quad (6)$$

where  $I(\xi_j = 1)$  is the indicator function with a value of 1 or 0 according to whether the causal variant  $j$  decreases the disease risk or not. Given a value of PAR, the relationship between MAF and GRR depicted by Equation (6) is shown in supporting information (Supplementary Figures S1 and S2). In addition, we also show the distributions of MAFs and GRRs of the causal variants in our 200 simulated data sets in Supplementary Figures S3 and S4, respectively.

To generate chromosomes of one individual, we randomly selected two chromosomes from the remaining 9,880 (= 10,000–120) chromosomes. The disease status of an individual possessing two chromosomes  $\{H_1, H_2\}$  was determined by

$$P(\text{affected} | \{H_1, H_2\}) = f_0 \times \prod_{k=1}^2 \prod_{j=1}^d GRR_j^{I(H_{k,j}=a_j)}, \quad (7)$$

in which  $f_0$  is the baseline penetrance, and  $a_j$  is the rare allele of the causal variant  $j$ . Following Li et al. [2010], we fixed  $f_0$  at 10%. In each replication, we continued the sampling procedure until 1,000 cases and 1,000 controls were reached. After generating the disease status based on Equation (7), the genotypes of all the causal variants were removed from our data sets. For each data set, we selected an analysis region with 20 tag SNPs to encompass the  $d$  causal variants.

To account for the haplotype ambiguity, we first inferred haplotype phases from unphased multimer genotypes with the EM algorithm by using the “haplo.em” function in the “haplo.stats” package [Schaid et al., 2002]. Note that all phasing algorithms assume HWE [Excoffier and Slatkin, 1995; Hawley and Kidd, 1995; Long et al., 1995], including the “haplo.em” function. Following Schaid et al. [2002], we assumed HWE in the pooled sample of cases and controls, and then phased cases and controls together (phasing cases and controls together provides a better control of type-I error rates than phasing cases and controls separately [Lin and Huang, 2007]). All possible haplotype pairs were considered with their posterior probabilities by treating the posterior probabilities as weights.

In addition to the nine haplotype-based tests, we also used the variable-threshold (VT) test program ([http://genetics.bwh.harvard.edu/rare\\_variants/](http://genetics.bwh.harvard.edu/rare_variants/)) to perform four pooling tests, including the fixed-threshold test with two thresholds of 1% and 5% [Morris and Zeggini, 2010], the weighted-sum test [Madsen and Browning, 2009] and the VT test [Price et al., 2010]. With a preliminary simulation, we found that the VT test was generally the most

powerful test among the four pooling tests. Therefore, in the following comparisons, we only present the result of the VT test [Price et al., 2010] as a representative of the four pooling tests.

## CONTINUOUS TRAITS

We further generated a continuous trait ( $Y$ ) by

$$Y = 10C_1 + 10C_2 + \beta_1g_1 + \beta_2g_2 + \dots + \beta_dg_d + e, \quad (8)$$

where  $C_1$  is a continuous covariate generated from a standard normal distribution,  $C_2$  is a dichotomous covariate taking a value of 0 or 1 each with a probability of 0.5,  $g_j$  is the number of causal allele on the  $j$ th causal variant ( $g_j = 0, 1, \text{ or } 2$ ),  $\beta_j$  is the effect size of the  $j$ th causal variant, and  $e$  is the random error. The random error,  $e$ , is assumed to have a normal distribution with a mean of zero and a variance of  $V_e$ . The effect sizes  $\beta$ 's and  $V_e$  were determined so that the heritability of each variant (we call it “marginal heritability”) was fixed at 0.05%, 0.1%, 0.15%, or 0.2% under the alternative hypothesis. The relationship between MAFs and  $\beta$ 's is shown by Supplementary Figure S5. The total sample size was set at 2,000. After generating the traits, the genotypes of all the causal variants were removed from our data sets. *HG* [Zhu et al., 2010] and *WHG* [Li et al., 2010] were proposed for case-control studies; therefore, they were not included in the comparisons for analyzing continuous traits.

In addition to specifying a normally distributed error term ( $e$ ), we also studied the situation when the random error came from a Gamma distribution with a shape parameter of 1 and a scale parameter of  $\sqrt{V_e}$ . The  $V_e$  and the effect sizes  $\beta$ 's (see Equation 8) were determined so that the marginal heritability was fixed at 0.05%, 0.1%, 0.15%, or 0.2% under the alternative hypothesis.

## SIMULATION RESULTS

### TYPE-I ERROR RATES

By setting the PAR or the marginal heritability at exactly 0%, we used the 200 simulated data sets to evaluate the type-I error rates. For each data set, 200 replications were performed. In the package “haplo.stats,” the default of the minimum number of counts for a haplotype to be included in the model is 5. Therefore, by default, haplotypes with frequencies less than  $\alpha_0 = 0.125\%$  (=  $5/(2 \times 2000)$ , where 2,000 is the total number of subjects) would be lumped into a single baseline group when using the “haplo.stats” package. To evaluate the influence of the choice of  $\alpha_0$ , we specified  $\alpha_0 = 0.125\%$ , 0.25%, and 1%, respectively. The corresponding minimum numbers of counts for a haplotype to be included in the model were 5, 10, and 40, respectively.

For similarity-based tests, following a practical strategy to provide robustness to genotyping errors [Lin and Lee, 2010; Lin and Schaid, 2009; Sha et al., 2007], we merged a haplotype with frequency less than a cutoff value  $\alpha_0$  with its most similar haplotype with frequency larger than  $\alpha_0$ . This  $\alpha_0$  is not necessary to be identical to the  $\alpha_0$  used in “haplo.stats.” However, to have a parallel comparison, we here also let  $\alpha_0 = 0.125\%$ , 0.25%, and 1% (where 1% is the cutoff value suggested by Sha et al. [2007]), respectively.




Fig. 1. Type-I error rates. The  $x$ -axis is the nominal significance level (where the leftmost point is  $10^{-4}$  and the rightmost point is  $10^{-2}$ ), and the  $y$ -axis is the type-I error rate. The different panels in the figure are arranged such that the cutoff value of haplotype frequencies is 0.125%, 0.25%, and 1% (from top to bottom) and the trait is binary, continuous with a normally distributed error term, and continuous with a Gamma-distributed error term (from left to right). In each panel, there are two curves for the *global* test (one is based on asymptotic  $P$ -values whereas the other is based on permutation  $P$ -values). For panels G and H, both the two curves for the *global* test are on the line  $y = x$  (the black bold line). For other panels, the one on the line  $y = x$  is for the *global* test based on permutation  $P$ -values and the one off the line  $y = x$  is for the *global* test with asymptotic  $P$ -values. Note that the ranges of the  $y$ -axis for the three trait distributions are different in order to present the curve of the *global* test based on asymptotic  $P$ -values.

Figure 1 presents the type-I error rates under various nominal significance levels, based on the 40,000 replications across the 200 simulated data sets, for each trait distribution and each  $\alpha_0$ . When  $\alpha_0 = 0.125\%$  or  $0.25\%$ , the asymptotic results of the *global* test are somewhat conservative for binary trait (panels A and D), but anticonservative for the continuous trait with a normally distributed error term (panels B and E) and the continuous trait with a Gamma-distributed error term (panels C and F). When  $\alpha_0 = 1\%$ , the asymptotic results of the *global* test are valid for binary

trait (panel G) and the continuous trait with a normally distributed error term (panel H), but still somewhat anticonservative for the continuous trait with a Gamma-distributed error term (panel I). All the other tests, including the *global* test based on permutation  $P$ -values, are valid in the sense that their type-I error rates correspond to the nominal significance levels. To have a fair comparison in power, we use permutations to evaluate the statistical significance for the *global* test (permutations are also required for *max* and *VT*). In the following simulations, the significances of *global* and

*max* are obtained with 1,000–20,000 permutations by a sequential Monte Carlo algorithm [Besag and Clifford, 1991], according to the default of the package “haplo.stats” [Schaid et al., 2002]. Moreover,  $\alpha_0$  is specified at 0.125% in the following simulations (as the default cutoff value in “haplo.stats”) for the *global*, *max*, and the similarity-based tests.

## POWER COMPARISONS—BINARY TRAITS

Figure 2 presents the power averaged over the 200 data sets representing a wide range of LD patterns, when the trait is binary. For each scenario (each combination of  $r$ , PAR, and  $d$ ) within each simulated data set, we performed 100 replications. The results show that the pooling methods such as the *VT* test are underpowered because they pool signals of common SNPs that do not well represent the information of uncommon variants. The *global*, *wei-SIMc-matching*, and *max* tests are the three most powerful tests. Specifically, the *max* test is slightly more powerful than the other two competitors when the PAR of each causal variant is smaller than or equal to 0.4% (the middle column of Figure 2) or when the number of causal variants is smaller than 20 (the right column of Figure 2). When there are more causal variants ( $d \geq 20$ ), there are usually more categories of disease-contributing haplotypes. In this situation, *global*, an omnibus test of all haplotype categories, is more powerful than *max*.

Overall, *global* is slightly more powerful than *wei-SIMc-matching*. The test statistic of *SIMc* is a summed product of genomic similarities and covariate-adjusted phenotypes (see Equation (4)). When the causal variants are all uncommon ( $MAF < 5\%$ ), *SIMc* is underpowered because few subjects have the causal variants and most subjects are similar by having no causal variants. By contrast, *global* lets each haplotype category (common or uncommon, as long as the frequency is larger than the cutoff  $\alpha_0$ ) account for an equal one degree of freedom (see Equation (3) of [Schaid et al., 2002]). Therefore, the association of uncommon haplotypes is more likely to be detected by *global*, rather than by *SIMc*.

The *wei-SIMc-matching* test, a variant of *SIMc*, is thus developed to enhance the ability of similarity-based approach to detect uncommon causal variants. The weight used in the *wei-SIMc-matching* test is in the order of 1/2 from the binomial standard deviation viewpoint. Through this work, we see that the *SIMc* test with this weight on haplotypes still cannot compete with the *global* test, when all the causal variants are uncommon ( $MAF < 5\%$ ). A larger order of weight can further boost the power to detect uncommon causal variants, however it will inevitably suffer from power loss if there are some common causal variants in that region [Tzeng et al., 2011].

Comparing *SIMc* with *SIMp*, the former is more powerful because it takes not only the within-group similarity but also the between-group similarity into considerations [Allen and Satten, 2009; Lin et al., 2012; Nolte et al., 2007; Sha et al., 2007]. *SIMp* has good power only when the causal variant was introduced at a common haplotype [Lin et al., 2012]. In our simulations, the disease status was influenced by multiple variants that usually resulted in multiple disease-contributing haplotypes with low frequencies. Therefore, *SIMp* was underpowered in this situation. Comparing the counting measure with the matching measure, the latter is more powerful because it captures the information of

identical-by-descent sharing more precisely [Lin and Lee, 2010; Lin and Schaid, 2009; Tzeng et al., 2009].

*HG* [Zhu et al., 2010] and *WHG* [Li et al., 2010] were not as powerful as the *global*, *wei-SIMc-matching*, and *max* tests. A main reason is that the data were split into a training set and a testing set. Both *HG* and *WHG* can be improved by using the entire sample for the co-classification stage and the same entire sample for the association stage, with permutations to adjust for the statistical significance. This strategy is computationally feasible when handling only top genes [Feng and Zhu, 2010]. However, it is computationally demanding for our comprehensive simulations.

## POWER COMPARISONS—CONTINUOUS TRAITS

Figure 3 presents the power averaged over the 200 data sets when the trait is continuous (100 replications for each scenario within each data set), given the nominal significance level of  $10^{-3}$ . The result given the nominal significance level of  $10^{-4}$  is presented in Supplementary Figure S7. When the error term is simulated from a normal distribution, the *wei-SIMc-matching*, *global*, and *max* tests are, again, the three most powerful tests. The *global* test is more robust to the percent of variants among the  $d$  causal variants that increase the trait value (the left upper panel of Figure 3). The *global* and *max* tests are slightly more powerful than the *wei-SIMc-matching* test when the marginal heritability of each causal variant is smaller than or equal to 0.1% (the middle upper panel of Figure 3) or when the number of causal variants is smaller than or equal to 20 (the right upper panel of Figure 3).

Note that different from other tests, the power of the *VT* test is not V-shaped, when the  $x$ -axis is the percent of variants among the  $d$  causal variants that increase the trait value (the first columns of Figure 3 and Supplementary Figure S7). This is because *VT* performs a right-tailed test in the program ([http://genetics.bwh.harvard.edu/rare\\_variants/](http://genetics.bwh.harvard.edu/rare_variants/)). Revising it to a two-tailed test can improve its power under a small  $r$  (the percent of variants among the  $d$  causal variants that increase the trait value).

When the error term is simulated from a Gamma distribution, *wei-SIMc-matching* is consistently the best method under all scenarios we evaluated (the bottom rows of Figure 3 and Supplementary Figure S7). In the package “haplo.stats,” the only choice of trait type for a continuous trait is “gaussian.” Therefore, we also specify “gaussian” as the trait type, when analyzing the continuous trait with a Gamma-distributed error term. Because the trait is skewed and is not following the normal (gaussian) distribution, the *global* and *max* tests (both performed with the package “haplo.stats”) suffer from power loss. This problem can be remedied by taking a logarithmic transformation on the trait. However, the skewness of an error term is not always easy to be recognized from the observed trait values. By contrast, the performances of the similarity-based tests are robust to the distribution of the traits (comparing the top rows and the bottom rows of Figure 3 and Supplementary Figure S7).

We also present the power stratified by the marginal heritability (given  $d = 40$ , and  $r = 100\%$ ) and then sorted by the percent of rare causal variants with  $MAF < 0.5\%$  (top rows of Supplementary Figures S10 and S11). Given many rare causal variants ( $MAF < 0.5\%$ ), *wei-SIMc-matching* is




Fig. 2. Comparison of power by  $r$  (the percent of high-risk variants among the  $d$  causal variants), PAR, and  $d$  (the number of causal variants), given a binary trait. The figure shows the power comparison by  $r$  (the left column, given PAR = 0.5% and  $d = 40$ ), PAR (the middle column, given  $d = 20$  and  $r = 100\%$ ), and  $d$  (the right column, given  $r = 100\%$  and PAR = 0.5%), respectively. The nominal significance levels were set at  $10^{-3}$  (top row) and  $10^{-4}$  (bottom row), respectively.

underpowered because very few subjects have the causal variants and most subjects are similar by having no causal variants. Furthermore, we also sorted the power by the LD pattern between the causal variants and the surrounding markers (bottom rows of Supplementary Figures S10 and S11). As expected, the power of all the tests improves as the average  $r^2$  increases. Generally speaking, *global* is more powerful than *wei-SIMc-matching* when the average  $r^2$  is smaller, whereas *wei-SIMc-matching* is more powerful when the average  $r^2$  is larger ( $d = 40$ , the average  $r^2$  was obtained by averaging the  $40 \times 20$   $r^2$ 's of any one causal variant and each of the 20 surrounding markers).

### CHOICE OF THE CUTOFF VALUE $\alpha_0$

In the above power comparisons, the cutoff value for haplotype frequencies was set at  $\alpha_0 = 0.125\%$ , the default value used in "haplo.stats." The haplotypes with frequencies less than  $\alpha_0$  were pooled into a single baseline group when we

used "haplo.stats." Besides, in the similarity-based tests, a haplotype with frequency less than  $\alpha_0$  was merged with its most similar haplotype with frequency larger than  $\alpha_0$ . Because the matching measure is a phase-dependent metric, the choice of  $\alpha_0$  may affect the performance of the *SIMp-matching*, *SIMc-matching*, and *wei-SIMc-matching* tests. To evaluate the influence on power of the five tests (*global*, *max*, *SIMp-matching*, *SIMc-matching*, and *wei-SIMc-matching* tests) with a different  $\alpha_0$ , we further performed simulations with  $\alpha_0 = 1\%$ . In Supplementary Figures S12–S14, we compare the result given  $\alpha_0 = 0.125\%$  with that given  $\alpha_0 = 1\%$ .

When analyzing binary traits (Supplementary Figure S12), all the five tests (*global*, *max*, *SIMp-matching*, *SIMc-matching*, and *wei-SIMc-matching* tests) became less powerful given an increased  $\alpha_0$  of 1%. As shown by Supplementary Figure S3, among all the causal variants in our simulation, the percent of rare causal variants (MAF < 1%) is 73.7%, whereas the percent of extremely rare causal variants (MAF < 0.125%) is 18.5%. The power loss given an increased




Fig. 3. Comparison of power by  $r$  (the percent of variants among the  $d$  causal variants that increase the trait value), the marginal heritability, and  $d$  (the number of causal variants), given a continuous trait. The figure shows the power comparison by  $r$  (the left column, given the marginal heritability = 0.2% and  $d = 40$ ), the marginal heritability (the middle column, given  $d = 40$  and  $r = 100\%$ ), and  $d$  (the right column, given  $r = 100\%$  and the marginal heritability = 0.2%), respectively. The nominal significance level was set at  $10^{-3}$ . The trait is continuous with a normally distributed error term (top row) and continuous with a Gamma-distributed error term (bottom row), respectively. The result given the nominal significance level of  $10^{-4}$  is shown by Supplementary Figure S7.

$\alpha_0$  of 1% is expected because haplotypes with frequencies less than 1% are more likely to tag the rare causal variants (MAF < 1%). However, they are lumped into a single baseline group when performing *global* and *max*, or merged with other commoner haplotypes when performing the *SIMp-matching*, *SIMc-matching*, and *wei-SIMc-matching* tests.

When analyzing continuous traits, again, similarity-based tests have a decrease in power when  $\alpha_0$  is increased to 1%, especially for the *wei-SIMc-matching* test whose power is boosted from up-weighting the similarities contributed by uncommon haplotypes. For *global* and *max*, however, generally the power improves when  $\alpha_0$  is increased to 1%. This contradicts the previous result for binary traits. Scoring many rare haplotypes (frequencies between 0.125% and 1%) in a model may weaken the power of the *global* and *max* tests, although we are unclear why this phenomenon only appears in analyzing continuous traits. On average, in each replication, ~18 haplotypes with frequencies larger than

1% and ~20 haplotypes with frequencies between 0.125% and 1% (see Supplementary Figures S15 and S16). Therefore, compared with  $\alpha_0 = 1\%$ , ~20 more haplotypes need to be scored in the model given  $\alpha_0 = 0.125\%$ . The many rare haplotypes (frequencies between 0.125% and 1%) may cause unstable estimation of the score vector  $\mathbf{U}_\psi$  and/or the variance-covariance matrix  $V_\psi$ .

### COMPUTATIONAL BURDEN

The computational burden to perform the *wei-SIMc-matching* test is reasonable because no permutation is required. When analyzing binary traits given PAR = 0.2%,  $d = 20$ ,  $r = 100\%$ , and the cutoff values for haplotype frequencies  $\alpha_0 = 0.125\%$ , the *wei-SIMc-matching* test on average takes, respectively, 0.9, 6.9, and 23.3 sec for a 20-SNP multimer set on 1,000, 2,000, and 3,000 subjects, given an

Intel Xeon workstation with 3.0 GHz of CPU and 2.0 GB of memory. The *global* test with 1,000–20,000 permutations on average takes 13.6, 61.3, and 145.9 sec, for analyzing 1,000, 2,000, and 3,000 subjects, respectively. The range of the required time for the *global* test is quite large (shown in Supplementary Figure S17), depending on the number of permutations (may range from 1,000 to 20,000) in each replication.

## SUMMARY OF SIMULATION RESULTS

The purposed *wei-SIMc-matching* test is among the most powerful tests for detecting uncommon causal variants (MAF < 5%), although it still cannot compete with the *global* test when most causal variants are very rare (MAF < 0.5%) or when the average  $r^2$  between the causal variants and the surrounding markers is extremely low ( $\leq 0.01$ ), as clearly shown by Supplementary Figure S10. However, the performance of the *wei-SIMc-matching* test is more robust to the trait distributions and the cutoff values for haplotype frequencies ( $\alpha_0$ ). Furthermore, it does not require permutations to obtain reliable statistical significance.

### APPLICATION TO A POPULATION-BASED RESEQUENCING STUDY FOR THE *ANGPTL4* GENE

We then applied the eight (for a continuous trait) or 10 (for a binary trait) tests to a population-based resequencing study for the *ANGPTL4* gene [Romeo et al., 2007, 2009]. To understand the role of *ANGPTL4* in lipid metabolism, Romeo et al. [2007, 2009] sequenced seven exons and the intron-exon boundaries of *ANGPTL4*. There were 3,551 subjects coming from a population-based probability sample of Dallas County residents, including 1,830 African Americans, 601 Hispanics, 1,045 European Americans, and 75 other ethnicities. In our analysis, we evaluated the performance of the various tests to detect associations between the plasma triglyceride levels and the uncommon variants in *ANGPTL4*, pretending that all the uncommon variants were *not* genotyped. We excluded the 75 subjects of other ethnicities from our analysis. Among the 93 variants, we kept two variants with MAF > 5% in the sample of the 3,476 (3,551–75 other ethnicities) subjects: P307P (MAF = 6.6%) and P389P (MAF = 6.5%). We deliberately excluded the variants with MAF less than 5% in order to mimic a commercial SNP array. To the best of our knowledge, E40K (MAF = 0.73%) and R278Q (MAF = 3.1%) are the only two variants reported to be associated with plasma triglyceride levels, based on the analyses for this resequencing data set [King et al., 2010; Maxwell et al., 2010; Romeo et al., 2007; Yi et al., 2011]. Our objective is to see whether the haplotype-based methods can detect the signal caused by the two reported uncommon variants (MAF < 5%), E40K and R278Q, which were both deliberately excluded from our analyses.

The log-transformed plasma triglyceride levels were first adjusted for age, sex, body mass index (BMI), and ethnicity (including three levels: African American, Hispanic, and European American) by performing a linear regression of log-transformed plasma triglyceride levels on these four covariates. The residuals ( $y_i - \hat{\mu}_i$ )'s were treated as continuous traits used in Equations (3) and (4) to per-

form the similarity-based tests. Because there were 468 subjects missing in age or BMI, the actual number of subjects for the analysis of the continuous trait was 3,008 (= 3,551–75–468). Following Romeo et al. [2007], we also created a binary trait by coding subjects in the top and bottom quartiles of the residuals as 1 (755 subjects) and 0 (744 subjects), respectively. The remaining subjects were excluded from the analysis. Therefore, the number of subjects for the analysis of the binary trait was 1,499 (= 755 + 744). We then tested for the association between the continuous/binary trait and the haplotypes formed by the two variants (P307P and P389P). There were 93 variants, generating 4,278 (=  $\binom{93}{2}$ ) possible combinations of any two variants.

We set the significance level at  $1.16 \times 10^{-5}$  (=  $0.05/4278$ ). The tests yielding significant results included *SIMc-counting* ( $P$ -value of the analysis for the continuous/binary trait =  $3.6 \times 10^{-10}/2.2 \times 10^{-9}$ ), *global* ( $< 10^{-6}/< 10^{-6}$ , with  $10^6$  permutations), *max* ( $6 \times 10^{-6}/5 \times 10^{-6}$ , with  $10^6$  permutations), and *wei-SIMc-matching* ( $6.3 \times 10^{-6}/1.8 \times 10^{-5}$ ). The above four tests can detect the association between the plasma triglyceride levels and the uncommon variants in *ANGPTL4* (E40K and R278Q [King et al., 2010; Maxwell et al., 2010; Romeo et al., 2007; Yi et al., 2011]), even when the uncommon variants were *not* genotyped. The results for the continuous trait and the binary trait were very similar.

## DISCUSSION

When performing haplotype-based tests, the question of how to choose the size of a multimarker set is still open [Schaid, 2004]. Although we let 20 SNPs form a multimarker set in our simulations, we also performed simulations by using only 10 SNPs to form a set (Supplementary Figures S18–S20). The relative power performances were very similar to the results by using 20 SNPs, but generally each test was less powerful than that by using 20 SNPs in a multimarker set. This is because larger multimarker sets may allow for measuring sharing over longer genomic sequences and lead to more power gains [Allen and Satten, 2009; Lin et al., 2012].

Through systematic simulations while considering a wide range of LD patterns, we find that although *wei-SIMc-matching* cannot compete with *global* in some situations (especially when most causal variants are very rare [MAF < 0.5%] or when the average  $r^2$  between the causal variants and the surrounding markers is extremely low ( $\leq 0.01$ ), as shown by Supplementary Figure S10), it is one of the best approaches for detecting uncommon causal variants (MAF < 5%) with surrounding common SNPs (MAF > 5%). In addition to the power, the merits of *wei-SIMc-matching* also include its robustness to the trait distributions and the cutoff values for haplotype frequencies ( $\alpha_0$ ). Furthermore, it is computationally feasible in the sense that no permutation is required to obtain reliable  $P$ -values.

Although *max* is slightly more powerful than *global* and *wei-SIMc-matching* under certain situations when analyzing binary traits, there is no analytic form for the distribution function of the *max* test statistic and permutation  $P$ -values are required. Permutation procedure is also required to obtain more reliable  $P$ -values for *global*, when the frequencies of some haplotype categories are low or when the trait is skewed (see Figure 1 or [Schaid et al., 2002]). When the significance level is much smaller than 0.05 as in whole-genome association studies, the estimation of  $P$ -values with

permutation procedures can be computationally challenging [Tong et al., 2010]. By contrast, *wei-SIMc-matching* provides reliable asymptotic  $P$ -values. As shown by Figure 1, its type-I error rates exactly correspond to the nominal significance levels.

The *max* test may not be very ideal because it evaluates the significance of a haplotype by assuming no effect of other haplotypes on the trait. Recall that the statistic for *global* is  $T_{global} = \mathbf{U}_\psi^T \mathbf{V}_\psi^{-1} \mathbf{U}_\psi$ , where  $\mathbf{U}_\psi$  is the score vector evaluated at  $\boldsymbol{\psi} = \mathbf{0}$  ( $\psi_k = 0$  for all  $k$ , in which  $\psi_k$  is the  $k$ th element of  $\boldsymbol{\psi}$ ). When performing *max* with the package “haplo.stats,” the test statistic is  $T_{max} = \max_k (U_{\psi,k}^2 / V_{\psi,k,k})$ , where  $U_{\psi,k}$  is the  $k$ th element of  $\mathbf{U}_\psi$  that is evaluated at  $\psi_k = 0$  for all  $k$ . It will be more precise to calculate the test statistic of *max* based on  $U_{\psi,k}^*$  (instead of  $U_{\psi,k}$ ), where  $U_{\psi,k}^*$  is evaluated at  $\psi_k = 0$  and  $\psi_l = \hat{\psi}_l$  ( $l \neq k$ ,  $\hat{\psi}_l$  is the maximum likelihood estimate of the effect of haplotype  $l$  in the unconstrained model). That is,  $U_{\psi,k}^*$  evaluates the significance of haplotype  $k$  while leaving the effects of the rest of haplotypes unconstrained.

In conclusion, compared with the other tests considered in this work, the *wei-SIMc-matching* test is to be recommended for the detection of uncommon causal variants with surrounding common SNPs, in light of its power and computational feasibility.

## ACKNOWLEDGMENTS

We thank the anonymous reviewers for their insightful and constructive comments and Drs. Jonathan C. Cohen and Helen H. Hobbs for kindly providing the Dallas Heart Study data. This work was supported in part by NIH grants GM081488 (N.L.), 5R01GM069430-07 (N.Y.), R00 RR024163 (D.Z.), and R01GM074913 (K.Z.) from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors declare that they have no conflict of interest.

## REFERENCES

- Allen AS, Satten GA. 2007. Statistical models for haplotype sharing in case-parent trio data. *Hum Hered* 64(1):35–44.
- Allen AS, Satten GA. 2009. A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson’s disease. *Genet Epidemiol* 33(8):657–667.
- Barrett JC, Cardon LR. 2006. Evaluating coverage of genome-wide association studies. *Nat Genet* 38(6):659–662.
- Besag J, Clifford P. 1991. Sequential Monte Carlo  $p$ -values. *Biometrika* 78:301–304.
- Bodmer W, Bonilla C. 2008. Common and rare variants in multifactorial susceptibility to common diseases. *Nat Genet* 40(6):695–701.
- Dempster AP, Laird NM, Rubin DB. 1977. Maximum likelihood estimation from incomplete data via the EM algorithm. *J R Stat Soc* 39:1–38.
- Excoffier L, Slatkin M. 1995. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. *Mol Biol Evol* 12(5):921–927.
- Feng T, Zhu X. 2010. Genome-wide searching of rare genetic variants in WTCCC data. *Hum Genet* 128(3):269–280.
- Gusev A, Kenny EE, Lowe JK, Salit J, Saxena R, Kathiresan S, Altshuler DM, Friedman JM, Breslow JL, Pe’er I. 2011. DASH: a method for identical-by-descent haplotype mapping uncovers association with recent variation. *Am J Hum Genet* 88(6):706–717.
- Han F, Pan W. 2010. A data-adaptive sum test for disease association with multiple common or rare variants. *Hum Hered* 70(1):42–54.
- Hawley ME, Kidd KK. 1995. HAPLO: a program using the EM algorithm to estimate the frequencies of multi-site haplotypes. *J Hered* 86(5):409–411.
- Imhof JP. 1961. Computing the distribution of quadratic forms in normal variables. *Biometrika* 48:419–426.
- Keating BJ, Tischfield S, Murray SS, Bhargava T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN, Chandrupatla HR, Hansen M, Ajmal S, Papanicolaou GJ, Guo Y, Li M, Derohannessian S, de Bakker PI, Bailey SD, Montpetit A, Edmondson AC, Taylor K, Gai X, Wang SS, Fornage M, Shaikh T, Groop L, Boehnke M, Hall AS, Hattersley AT, Frackelton E, Patterson N, Chiang CW, Kim CE, Fabsitz RR, Ouwehand W, Price AL, Munroe P, Caulfield M, Drake T, Boerwinkle E, Reich D, Whitehead AS, Cappola TP, Samani NJ, Lusis AJ, Schadt E, Wilson JG, Koenig W, McCarthy MI, Kathiresan S, Gabriel SB, Hakonarson H, Anand SS, Reilly M, Engert JC, Nickerson DA, Rader DJ, Hirschhorn JN, Fitzgerald GA. 2008. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. *PLoS ONE* 3(10):e3583.
- King CR, Rathouz PJ, Nicolae DL. 2010. An evolutionary framework for association testing in resequencing studies. *PLoS Genet* 6(11):e1001202.
- Kitsios GD, Zintzaras E. 2010. An NOS3 haplotype is protective against hypertension in a Caucasian population. *Int J Hypertens* 2010:865031.
- Li B, Leal SM. 2008. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. *Am J Hum Genet* 83(3):311–321.
- Li Y, Byrnes AE, Li M. 2010. To identify associations with rare variants, just WHaIT: weighted haplotype and imputation-based tests. *Am J Hum Genet* 87(5):728–735.
- Lin DY, Huang BE. 2007. The use of inferred haplotypes in downstream analyses. *Am J Hum Genet* 80(3):577–579.
- Lin WY, Lee WC. 2010. Discovering joint associations between disease and gene pairs with a novel similarity test. *BMC Genet* 11:86.
- Lin WY, Schaid DJ. 2009. Power comparisons between similarity-based multilocus association methods, logistic regression, and score tests for haplotypes. *Genet Epidemiol* 33(3):183–197.
- Lin WY, Tiwari HK, Gao G, Zhang K, Arcaroli JJ, Abraham E, Liu N. 2012. Similarity-based multimarker association tests for continuous traits. *Ann Hum Genet* 76:246–260.
- Lin WY, Zhang B, Yi N, Gao G, Liu N. 2011. Evaluation of pooled association tests for rare variant identification. *BMC Proc* 5 (Suppl 9):S118.
- Liu PY, Zhang YY, Lu Y, Long JR, Shen H, Zhao LJ, Xu FH, Xiao P, Xiong DH, Liu YJ, Recker RR, Deng HW. 2005. A survey of haplotype variants at several disease candidate genes: the importance of rare variants for complex diseases. *J Med Genet* 42(3):221–227.
- Long JC, Williams RC, Urbanek M. 1995. An E-M algorithm and testing strategy for multiple-locus haplotypes. *Am J Hum Genet* 56(3):799–810.
- Madsen BE, Browning SR. 2009. A groupwise association test for rare mutations using a weighted sum statistic. *PLoS Genet* 5(2):e1000384.
- Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorf LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. 2009. Finding the missing heritability of complex diseases. *Nature* 461(7265):747–753.

- Maxwell TJ, Bendall ML, Staples J, Jarvis T, Crandall KA. 2010. Phylogenetics applied to genotype/phenotype association and selection analyses with sequence data from *angptl4* in humans. *Int J Mol Sci* 11(1):370–385.
- Morris AP, Zeggini E. 2010. An evaluation of statistical approaches to rare variant analysis in genetic association studies. *Genet Epidemiol* 34(2):188–193.
- Nelder JA, Wedderburn RWM. 1972. Generalized linear models. *J R Stat Soc Ser A* 135:370–384.
- Nolte IM, de Vries AR, Spijker GT, Jansen RC, Brinza D, Zelikovsky A, Te Meerman GJ. 2007. Association testing by haplotype-sharing methods applicable to whole-genome analysis. *BMC Proc* 1 (Suppl 1):S129.
- Price AL, Kryukov GV, de Bakker PI, Purcell SM, Staples J, Wei LJ, Sunyaev SR. 2010. Pooled association tests for rare variants in exon-resequencing studies. *Am J Hum Genet* 86(6):832–838.
- Rinaldo A, Bacanu SA, Devlin B, Sonpar V, Wasserman L, Roeder K. 2005. Characterization of multilocus linkage disequilibrium. *Genet Epidemiol* 28(3):193–206.
- Roeder K, Bacanu SA, Sonpar V, Zhang X, Devlin B. 2005. Analysis of single-locus tests to detect gene/disease associations. *Genet Epidemiol* 28(3):207–219.
- Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, Cohen JC. 2007. Population-based resequencing of *ANGPTL4* uncovers variations that reduce triglycerides and increase HDL. *Nat Genet* 39(4):513–516.
- Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, Cohen JC. 2009. Rare loss-of-function mutations in *ANGPTL* family members contribute to plasma triglyceride levels in humans. *J Clin Invest* 119(1):70–79.
- Sboner A, Mu XJ, Greenbaum D, Auerbach RK, Gerstein MB. 2011. The real cost of sequencing: higher than you think! *Genome Biol* 12(8):125.
- Schaffner SF, Foo C, Gabriel S, Reich D, Daly MJ, Altshuler D. 2005. Calibrating a coalescent simulation of human genome sequence variation. *Genome Res* 15(11):1576–1583.
- Schaid DJ. 2004. Evaluating associations of haplotypes with traits. *Genet Epidemiol* 27(4):348–364.
- Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. 2002. Score tests for association between traits and haplotypes when linkage phase is ambiguous. *Am J Hum Genet* 70(2):425–434.
- Scheffe H. 1959. *The Analysis of Variance*. New York: Wiley.
- Sha Q, Chen HS, Zhang S. 2007. A new association test using haplotype similarity. *Genet Epidemiol* 31(6):577–593.
- Tong L, Yang J, Cooper RS. 2010. Efficient calculation of P-value and power for quadratic form statistics in multilocus association testing. *Ann Hum Genet* 74(3):275–285.
- Tzeng JY, Devlin B, Wasserman L, Roeder K. 2003. On the identification of disease mutations by the analysis of haplotype similarity and goodness of fit. *Am J Hum Genet* 72(4):891–902.
- Tzeng JY, Zhang D, Chang SM, Thomas DC, Davidian M. 2009. Gene-trait similarity regression for multimer-based association analysis. *Biometrics* 65(3):822–832.
- Tzeng JY, Zhang D, Pongpanich M, Smith C, McCarthy MI, Sale MM, Worrall BB, Hsu FC, Thomas DC, Sullivan PF. 2011. Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression. *Am J Hum Genet* 89(2):277–288.
- WTCCC. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447(7145):661–678.
- Yi N, Liu N, Zhi D, Li J. 2011. Hierarchical generalized linear models for multiple groups of rare and common variants: jointly estimating group and individual-variant effects. *PLoS Genet* 7(12):e1002382.
- Zeggini E. 2011. Next-generation association studies for complex traits. *Nat Genet* 43(4):287–288.
- Zhu X, Fejerman L, Luke A, Adeyemo A, Cooper RS. 2005. Haplotypes produced from rare variants in the promoter and coding regions of *angiotensinogen* contribute to variation in *angiotensinogen* levels. *Hum Mol Genet* 14(5):639–643.
- Zhu X, Feng T, Li Y, Lu Q, Elston RC. 2010. Detecting rare variants for complex traits using family and unrelated data. *Genet Epidemiol* 34(2):171–187.